Show simple item record

dc.contributor.authorValentine, J.
dc.contributor.authorStannage, K.
dc.contributor.authorFabian, V.
dc.contributor.authorEllis, K.
dc.contributor.authorReid, S.
dc.contributor.authorPitcher, C.
dc.contributor.authorElliott, Catherine
dc.identifier.citationValentine, J. and Stannage, K. and Fabian, V. and Ellis, K. and Reid, S. and Pitcher, C. and Elliott, C. 2015. Muscle Histopathology in Children with Spastic Cerebral Palsy Receiving Botulinum toxin Type A. Muscle & Nerve. 53 (3): pp. 407-414.

Introduction: Botulinum toxin A (BoNTA) is routine treatment for hypertonicity in children with cerebral palsy (CP). Method: Single blind prospective cross sectional study of 10 participants (mean age 11 years,7 months) was done to determine the relationship between muscle histopathology and BoNTA in treated medial gastrocnemius muscle of children with CP. Open muscle biopsies were taken from medial gastrocnemius muscle and vastus lateralis (control) during orthopedic surgery. Results: Neurogenic atrophy in the medial gastrocnemius was seen in 6 participants between 4 months to 3 years post BoNTA. Type 1 fiber loss with type 2 fiber predominance was significantly related to the number of BoNTA injections (r = 0.89, P < 0.001). Discussion: The impact of these changes in muscle morphology on muscle function in CP is not clear. It is important to consider rotating muscle selection or injection sites within the muscle or allowing longer time between injections.

dc.publisherJohn Wiley & Sons, Inc
dc.subjectbotulinum toxin
dc.subjectmedial gastrocnemius hypertonia
dc.subjectCerebral Palsy
dc.subjectmuscle histopathology
dc.subjectneurogenic atrophy
dc.titleMuscle Histopathology in Children with Spastic Cerebral Palsy Receiving Botulinum toxin Type A
dc.typeJournal Article
dcterms.source.titleMuscle & Nerve
curtin.accessStatusFulltext not available
curtin.facultyFaculty of Health Sciences

Files in this item


This item appears in the following Collection(s)

Show simple item record